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Amino polystyrene nanospheres are shown to be efficient and controllable delivery devices,
capable of transporting several bioactive cargoes. Recently, the design of a new device for pro-
drug activation, using these nanospheres with palladium encapsulated onto them, has been
developed successfully. To study the influence of the cellular uptake of these nanodevices, we
investigated the cellular response of human embryonic kidney cells (HEK-293T) and murine
fibroblasts (L929) treated with empty or palladium-conjugated amino polystyrene nanospheres.
To identify differentially expressed proteins, we performed an exhaustive proteomic analysis.
In accordance with genomic data previously obtained, the uptake of the empty nanospheres
did not induce significant variation in protein expression levels. Following the treatment with
palladium-conjugated nanospheres, some changes in protein profiles in both cell lines were
observed; these alterations affect proteins involved in cell metabolism and intracellular trans-
port. No key regulator of the cell cycle result was differentially expressed after the treatment,
confirming that these innovative drug delivery systems are harmless and well tolerated by the
cells.
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1 Introduction
The study of proteome can provide useful information on
the types and quantities of proteins produced by a living
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system in a specific moment, as well as details on the net-
work of protein–protein interactions [1–4]. Concerning the
use of proteomic analysis to characterize the cellular response
induced by nanospheres treatment, there are few existing
studies. The apoptotic/necrotic phenotype observed in hu-
man chronicmyelogenous leukemia cells incubatedwith gold
nanospheres is mainly due to stress response mediated by
unfolded protein associated with endoplasmic reticulum [5].
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A comparative proteomic study has been reported to iden-
tify the signaling pathways leading to oxidative stress in hu-
man bronchial epithelial cells induced by titanium dioxide
nanospheres [6]. Over the last few decades, interest in drug
delivery has been exponentially grown. However, its appli-
cation in the development of specific and efficient therapies
especially in cancer treatment, remains a challenge still open
[7]. Encouraging results have been obtained following the syn-
thesis of nanospheres, polymeric matrix in the form of nano-
sized colloids, that share many characteristics and offer sev-
eral advantages compared to other drug delivery systems [8,9].
Currently, more than 150 different companies are develop-
ing nanospheres-based therapeutic products [10,11]. In previ-
ous studies Sanchez-Martin et al. synthesized monodisperse
amino-functionalized polystyrene nanospheres and their cel-
lular uptake successfully demonstrated in a broad range of
cell types [12–15]. Relevant cargoes such as proteins, oligonu-
cleotides, both DNA plasmids and siRNA, ion sensors,
fluorophores, andmetals such as palladium have been conju-
gated to them and successfully delivered inside cells. Further-
more, by gene-expression profiling studies it was shown that
nanospheres did not induce significant alteration of bead-
fected cell transcriptomes [12]. We have recently developed
a method for the selective activation of biomolecules inside
living cells using a metal so toxic as palladium (Pd), with-
out inducing cellular death by immobilizing palladium on
amino-polysterene nanospheres [16]. The employment of Pd
as exogenous catalyst would allow to design highly effective
therapeutic platforms devoid of side effects, such as the sys-
temic administration of a pro-drug that is activated only in
cells containing Pd nanospheres [17]. Given the many pos-
sibilities and applications of nanotechnology, the present
project arose from the need to assess side effects induced
by treatment with amino-polystyrene nanospheres on cellu-
lar functionality. For this purpose, we have chosen human
embryonic kidney cells (HEK-293T) and murine fibroblasts
(L929) as cell models as they were used previously for gene-
expression profiling studies [12]. Following treatment with
empty and palladium-conjugated nanospheres, a cell viabil-
ity study and a proteomic study have been carried out. The
significant changes in protein levels of treated cells are very
limited. These changes occur mainly in cells treated with
Pd-nanospheres. Future studies will be focused on the pro-
teomic analysis of different cancer cells treated with these
palladium-nanospheres together with antitumoral prodrugs
to go one step closer to in vivo evaluation of this promising
therapeutic nanodevice.
2 Materials and methods
2.1 Chemicals and reagents
Protease inhibitor cocktail, EGTA, Bradford reagent,
BSA, DMEM, trypsin/EDTA, FBS, L-glutamine, penicillin/
streptomycin, and PBS were purchased from Sigma-Aldrich
(Saint Louis, MO, USA). Annexin-V-FLUOS Staining Kit was
obtained from Roche (Penzberg, Germany).
2.2 Nanospheres synthesis
Aminomethyl polystyrene nanospheres (205 and 500 nm)
were prepared by dispersion polymerization as earlier de-
scribed [18]. The synthesis of 205 and 500 nmPd0-conjugated
nanospheres was performed as previously reported [16]. Flu-
orescent labelling of these nanosphers was done by conjuga-
tion of 5(6)-carboxyfluorescein using carbodiimide chemistry
protocol already described [16].
2.3 Cell cultures and beadfection
Human embryonic kidney cells (HEK-293T) and murine fi-
broblasts (L929) were provided by the Fundamental Biology
Unit of the Center of Scientific Instrumentation of the Uni-
versity of Granada. Cell lines were maintained in DMEM
supplemented with 10% FBS, 4mM L-glutamine and 1% v/v
penicillin-streptomycin, at 37C and 5% CO2 humidified at-
mosphere in a cell culture flask until 70–80% cell confluence.
To beadfection, 2 × 106 HEK-293 and 1 × 106 L929 were
seeded in 75 cm2 flasks in growthmedium (15mL). After one
day, the culture media was substituted with fresh medium
containing 86 g/mL empty and Pd-conjugated nanospheres
(205 and 500 nm in diameter). Cells were incubated with
nanospheres at 37C, 5% CO2 for 48 h. Culture media were
not changed during the beadfection. Untreated cells were
used as controls.
2.4 Cellular uptake
A total of 2.5× 105 HEK-293T and 1.4× 105 L929were seeded
in 6-well plates and grown for 24 h prior to incubation with
86 g/mL empty and Pd conjugates nanospheres labelled
with FITC. After 48 h of incubationwith nanospheres at 37C,
cells were washed with PBS, harvested by trypsinization, and
centrifuged at 2721 × g for 5 min. Then, the cellular pellets
were resuspended in 500 L of PBS and analyzed by flow
cytometry using a Becton Dickinson FACScan flow cytome-
ter. Untreated cells and cells treated with naked nanospheres
(without fluorescent labeling) were used as controls.
2.5 Cell viability assay
The cytotoxic effects of empty andPd-conjugatesnanospheres
were assayed by the Annexin-V-FLUOS Staining Kit (Roche).
Briefly, HEK-293T and L929 were seeded in 6-well plates
(2.5× 105 and 1.4× 105cells/well, respectively) and, after 24 h
of plating, maintained for 48 h with empty or Pd-conjugates
nanospheres (86g/mL). After incubation, cells werewashed
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once with PBS, detached with trypsin/EDTA and centrifuged
at 272 × g for 5 min. As a positive control of apoptosis, HEK-
293T and L929, cells treated with 10 mM H2O2 for 1 h were
used [17]. The stained cells were analyzed on Becton Dickin-
son FACScan flow cytometer system using 488 nm excitation
and 515 nm band-pass filter for fluorescein detection and a
filter 600 nm for PI detection. Gating was implemented on
the basis of the staining profile of positive controls and of
untreated cells (negative control).
2.6 Samples preparation and 2DE
HEK-293T and L929 cells were washed once with sterile
PBS and lysed with 1 mL of RIPA buffer (50 mM Tris–HCl
pH 8.0, 150 mM NaCl, 1% v/v Igepal CA-630 (NP-40), 2 mM
EGTA, 0.5% w/v sodium deoxycholate and 0.1% w/v SDS,
supplemented with a cocktail of protease and phosphatase
inhibitors (Sigma) [19]. Protein samples were separated by
centrifugation at 8000 × g for 10 min, then they were iso-
lated by precipitation overnight with five volumes of cold
acetone (−20C) [20]. After centrifugation at 8000 × g for
10 min at room temperature (RT), supernatants containing
the interference substances were removed and protein pel-
lets were dried leaving uncapping tubes at RT for 30 min.
Dry pellets were redissolved in 8 M urea, 4% w/v CHAPS,
65 mM DTT [19] and protein concentration was determined
by Bradford assay in microplate. IEF was performed on IPG
strips (BioRad) having pH 3–10 nonlinear and 18 cm length
by using an Ettan IPGphorTM system with Ettan IPGphor
ManifoldTM (GE Healthcare). Briefly, IPG strips were rehy-
drated overnight with 350 L of rehydration solution (8 M
urea, 2% w/v CHAPS, 0.5% w/v DTE) supplemented with
0.5% v/v carrier ampholyte (Biorad) and a trace of bromophe-
nol blue by using IPGbox [21]. Then the strips were trans-
ferred to Ettan IPGphor Manifold, covered with inert oil.
A total of 600 g of protein sample was loaded into the
sample cups placed near the anode. The strips were fo-
cused at 16C according to the following electrical condi-
tions: 200 V for 1 h, 300 V for 1 h, from 300 to 3500 V in
30 min, 3500 V for 4 h, 5000 for 2 h, from 5000 to 8000 V in
30 min, and 8000 V until a total of 90 000 V/h was reached,
with a limiting current of 50 A/strip [21]. After IEF, the
equilibration steps were performed in 6 M urea, 2% w/v
SDS, 2% w/v DTE, 30% v/v glycerol, and 0.05 M Tris-HCL
pH 6.8 for 10 min, then in the same buffer containing 2.5%
w/v iodoacetamide (IA) in place of DTE, for other 10 min
[21]. The equilibrated strips were placed onto the edge of
9−16%polyacrylamide linear gradient gels (18 cm× 20 cm×
1.5mm) and covered by 0.5%w/v heated low-melting agarose
in SDS electrophoresis running buffer (25 mMTris, 192 mM
glycine, 0.1% w/v SDS, pH 8.3) [21]. Second dimension was
carried out in a PROTEAN II xi cell gel electrophoresis unit
(Bio-Rad) at 10C and at 40 mA/gel constant current, until
the dye front reached the bottom of the gel [21]. Gels were
stained following colloidal Coomassie staining protocol [22].
2.7 Images acquisition and statistical analysis
We performed three independent biological replicates for
each nanosphere type (205 and 500 nm empty; 205 and
500 nm Pd conjugated nanospheres), and we carried out two
technical replicates (two 2DE) for each sample. Untreated
cells were used as controls. Colloidal Commassie-stained gels
were digitized using the Epson expression 1680 PRO scan-
ner. The gel images were saved with a resolution of 300 dpi
and as 16-bit TIFF format. Image analysis was carried out us-
ing the Progenesis SameSpots software version 4.0 (Nonlin-
ear Dynamics, UK) which allows spot detection, background
subtraction, and protein spot volume quantification. The gel
image showing the highest number of spots and the best
protein pattern was chosen as the reference image and its
spots were then matched across all gels. This reference im-
age was used to quantify and normalize the spot volumes.
The spot volumes were normalized in each gel as relative
volume (volume percentage), by dividing the raw quantity of
each spot by the total quantity of all the spots included in the
reference gel. Statistical analysis was performed using default
parameters of the Progenesis SameSpots Stat module. The
log10-normalized spot volumewas used for the analysis as the
log transformation improves normality. The univariate data
analysis was performed as one-way ANOVA (p < 0.05) on
each spot individually. Principal component analysis (PCA)
was performed as multivariate test. The spots with a p-value
less than 0.05 and with a fold change higher than two were
subjected to MS analysis [21]. The spots with a p-value less
than 0.05, were subjected to multiple comparisons Tukey’s
test using Daniel’s XL Toolbox version XYZ, an Add-In for
Microsoft Excel, by Daniel Kraus (Wu¨rzburg, Germany).
2.8 Protein identification by MS
The spots of interest were manually excised and destained
in a solution with 50 mM ammonium bicarbonate and
50% v/v ACN, then dehydrated in ACN. By using trypsin
solution, the spots were rehydrated and digested overnight
at 37C. Each protein digest (0.75 L) was spotted onto
the MALDI target and allowed to air dry. Then 0.75 L of
matrix solution (saturated solution of CHCA in 50% v/v
ACN and 0.5% v/v TFA) was applied to the sample which
was then dried again [23]. Protein identification was car-
ried out using an Ultraflex III MALDI-TOF/TOF mass
spectrometer (BrukerDaltonics) equipped with a 200 Hz
smartbeamTM I laser. MS analysis was performed in the pos-
itive reflector mode according to the following parameters:
80 ns of delay; ion source 1:25 kV; ion source 2: 21.75 kV;
lens voltage: 9.50 kV; reflector voltage: 26.30 kV; and reflector
2 voltage: 14.00 kV. The applied laser wavelength and fre-
quency were 353 nm and 100 Hz, respectively, and the
percentage was set to 46%. Final mass spectra were pro-
duced by averaging 1500 laser shots targeting five dif-
ferent positions within the spot. Spectra were acquired
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automatically and the Flex Analysis software version 3.0
(Bruker) was used for their analysis and for the assign-
ment of the peaks. The applied software generated a list
of peaks up to 200, using a S/N of 3 as threshold for peak
acceptance. Protein identification by Peptide Mass Finger-
print was performed by uploading data to MASCOT for
database searching on the Matrix Science (London, UK,
http://www.matrixscience.com) and searched against into
UniProtKB protein database (http://www.uniprot.org/). Tax-
onomy was limited toHomo sapiens or toMus musculus, mass
tolerance set to 100 ppm and one missed cleavage was al-
lowed. Alkylation of cysteine by carbamidomethylation was
set as fixed modification, while oxidation of methionine was
allowed as variable modification. Search parameters used to
accept identifications included the extent of sequence cov-
erage, the number of matched peptides, and a probabilistic
score at p < 0.05 [19, 24].
2.9 Protein validation by Western blot
Cells were lysated in ice-cold RIPA buffer plus protease and
phosphatase inhibitor cocktails for mammalian cells (Sigma-
Aldrich, St. Gallen, CH). A total of 15 g of protein extract
were separated by 12% SDS-PAGE and blotted onto PVDF
membrane by using Trans-blot Turbo (Bio-Rad) [19]. West-
ern immunoblottings were performed using a mouse mono-
clonal antibody against vimentin (Thermo Scientific) diluted
1000-fold, and a rabbit polyclonal antibody against phospho-
glycerate mutase (Abcam, Cambridge, UK) diluted 2000-fold.
Anti-mouse (1:2000) and anti-rabbit (1:10 000) peroxidase-
conjugated secondary antibodies were purchased from Cell
Signaling and TEMA Ricerca, respectively. The reaction was
detected with an ECL kit (Thermo Scientific). Quantitative
analysis was carried out by densitometric analysis of blotted
PVDF, stained with Coomassie brilliant blue R-250, by us-
ing Quantity One Software (Bio-Rad) [20]. Statistical analysis
was performed by Student’s t-test and p-values lower than
0.05 were evaluated as significant. The intensities of the im-
munostained bands were normalized with the total protein
intensities measured by Coomassie brilliant blue R-250 from
the same blot [20].
3 Results
3.1 Evaluation of cellular uptake efficiency and cell
viability of Pd conjugated nanospheres
Uniform aminomethyl polystyrene nanospheres of 205 and
500 nm of diameter were synthesized by dispersion polymer-
ization from styrene-based monomers and Pd-conjugated
nanospheres (205Pd and 500Pd) were prepared following
a synthetic procedure previously reported [16]. In order to
verify the uptake and toxicity of obtained Pd-conjugated
nanospheres, these were incubated for 48 h with human
embryonic kidney cells (HEK-293T) and murine fibroblasts
(L929). Following incubation, the cells were detached and
analyzed in duplicate by flow cytometry to verify the uptake
efficiency. The results, expressed as percentage of fluores-
cent cells (average of three independent experiments) are
reported in the bar plots of Fig. 1A. Concerning HEK-293T
cells, 205Pd, 500, and 500Pd nanospheres were internalized
with more efficiency than 205 empty nanospheres (70, 82,
and 85% in comparison to 65%, respectively) with a p value
less than 0.05. L929 cells are able to internalize with the
same efficiency all the four different types of nanospheres.
To investigate if nanosphere uptake induces cytotoxicity, we
carried out a flow cytometry analysis in order to determine
the amounts of viable, apoptotic, or necrotic cells. The results
are depicted in Fig. 1B for HEK-293T and 1C for L929 cells.
An independent analysis on the two cells lines treated with
10 mM H2O2 was carried out in order to have a positive con-
trol for apoptosis. We usedH2O2 to induce apoptosis because
it is an oxygen free radical source able to induce apoptosis in
many kinds of cells. As shown in plots, in both cell lines the
cell viability is not influenced by the uptake of the different
nanospheres. In fact, following 2 days of incubation, more
than 90% of cell population is still viable. The corresponding
bar blots show the relative percentages of the different cell
populations: alive, early apoptotic, and late apoptotic/necrotic
cells for each experimental condition. Either in HEK-293T or
L929, the percentages of apoptotic or necrotic cells appear
negligible and not significant compared to that of viable cells,
underlining that empty and Pd-conjugated nanospheres do
not affect viability in these cell lines. Regarding the positive
controls for apoptosis, 50% of the cells show a late apoptotic
phenotype.
3.2 Protein expression profiles of treated HEK-293T
and L929 cells
To investigate in detail the effects induced by the nanosphere
uptake on cells, the protein expression profiles were ana-
lyzed through comparative proteomic study. Following the
incubation, cells were lysed and the protein extracts were
separated by 2DE. Overall, 30 gels were analyzed by Proge-
nesis Samespots software for each cell line, in order to re-
duce the experimental and biological variability, as well as to
obtain statistically significant results. Approximately, more
than 2000 spots were detected in each colloidal Coomassie-
stained 2DE gels. All the gels analyzed showed a rela-
tively similar protein pattern, indicating that the treatment
with nanospheres affects only partially the proteomic pro-
files of HEK-293T and L929 cells (Supporting Information
Fig. 1).
Between the spots differentially expressed, were consid-
ered only the spots statistically significant (ANOVA  0.05)
and with a fold change 2. In HEK293T cells the protein ex-
pression profiles of 17 proteins were found changed. Among
these, five spots (2, 3, 5, 6, and 13) resulted more abundant
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Figure 1. Evaluation of uptake effi-
ciency and cell viability by flow cy-
tometry. (A) Percentage of fluorescent
labeled cells after treatment. (*) Indi-
cates a significant difference between
the uptake of 205 empty nanospheres
and 500 (empty and Pd) nanospheres.
(B and C) Cells were stained with
Annexin-V/Propidium Iodide: flow cy-
tometry plots and bar plots show the
percentage of viable, early apoptotic,
and late apoptotic/necrotic HEK-293T
(B) and L929 cells (C) following in-
cubation with the different types of
nanospheres for 48 h.
and 12 were less abundant. Concerning L929 cells we found
increased 24 protein spots compared to controls. Figure 2
reports the locations of these protein spots marked with ar-
rows in the representative gel images. The differences among
the 2D-electrophoretic profiles obtained from the five dif-
ferent experimental conditions for each cell type were sub-
jected to a PCA. In the resulting PCA plots (Fig. 2C and
D), we observe five different groups, underlining a good
reproducibility of data sets. The differences in protein ex-
pression profiles are more evident in both cells treated with
Pd-conjugated nanospheres. The empty nanospheres groups
(205 and 500) are spread very close to the control groups,while
the 205Pd and 500Pd are localized in the opposite side of the
plots.
3.3 Identification of protein variations in empty and
Pd conjugated nanospheres treated cells
3.3.1 Altered Proteins in HEK-293T cells
Among the 17 protein spots excised from preparative gels,
we identified by MS 13 proteins reported in Table 1. Not all
protein spots of interest were identified, both because they
are also formed by poorly represented proteins and because
MS presents inherent sensitivity limits. The data obtained
confirmed that the variations in protein expression profiles
occur in cells treated with 205Pd or 500Pd in comparison to
empty nanospheres and control cells, as previously observed
by PCAplots.We found two proteins involved in transcription
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Figure 2. Coomassie-colloidal 2DE gels and
principal component analysis. Representative
2DE gels of HEK-293T (A) and L929 cells (B).
Arrows and numbers (corresponding to those
reported in Table 1) show differentially ex-
pressed protein spots. Protein spots marked
with circles were identified by MS. PCA plots
of HEK-293T (C) and L929 (D).
as less abundant proteins: the far upstream element-binding
protein 2 (spot 1), that plays a role in mRNA trafficking and
the protein Pirin (spot 9), a transcriptional coregulator; one
protein is involved in protein folding control: the Prefoldin
subunit 2 (spot 15) and some glycolytic enzymes, such as
phosphoglycerate mutase (spot 11),  and  enolase (a mix
found in spot 4) and triosephosphate isomerase (spot 12). In
HEK-293T cells, among the protein spots identified as more
abundant after treatment with Pd nanospheres, we found one
protein showing an antiapoptotic activity in cells (Anamorsin;
spot 5), underlining that the cell viability is not affected by
nanosphere uptake.
3.3.2 Altered Proteins in murine L929 cells
Nineteen protein spots, listed in Table 1, showed a signif-
icant ANOVA value with Pd-conjugated nanospheres treat-
ment. All the proteins identified showed a more abundant
expression levels after treatment. Most of affected proteins
are involved in cytoskeletal rearrangment and in cell–cell and
cell-matrix adhesion. No differentially expressed protein was
found in common between the murine and human cell lines;
probably because the mechanism of internalization is differ-
ent between two cell types or, more likely, because it involves
different and not conserved proteins between two species.
3.4 Validation of proteomic results
To determine which processes were affected by empty and
Pd-conjugated nanospheres, a functional classification anal-
ysis of all identified proteins was performed using Pan-
ther software (http://www.pantherdb.org/) [25]. The results
are reported in Fig. 3. Regarding the proteins identified in
treated HEK-293T cells (A), they were grouped into six cate-
gories, most of them were included in “catalytic activity” and
“binding” categories. In L929 cells (B) the proteins identified
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Table 1. Differentially expressed protein spots identified by MALDI-TOF analysis. Search was performed in UniProtKB database using
MASCOT software.
Spot
noa)
Protein name ACb) Theoretical
Mw (kDa)/
pIc)
Scored) No. of
matched
peptidese)
Sequence
coveragef)
Foldg) p-valueh) Tukey’s post
hoc multiple
comparisonsi)
HEK293T
1 Far upstream element-binding
protein 2
Q92945 6.8/73.11 251 18/20 34 −2.2 1.2e–02 C/D
C/E
4 Mix: Alpha-enolase
Beta-enolase
P06733
P13929
7.0/47.17
7.6/46.99
188
70
23/56
12/56
63
31
−2.1 2.1e–02 C/E
5 Anamorsin Q6FI81 5.4/33.58 191 12/16 40 2 1.2e–02 A/D C/D
6 COP9 signalosome complex
subunit 4
Q9BT78 5.6/46.27 199 21/47 61 3.2 3.2e–02
7 Quinone oxidoreductase-
like protein 1
O95825 5.5/38.70 102 9/23 33 −3.3 1.8e–02
8 Nuclear inhibitor of protein
phosphatase 1
Q12972 6.9/38.48 102 9/24 34 −2.4 4.4e-02
9 Pirin O00625 6.4/32.11 101 9/27 38 −3.3 8.9e–04 A/D C/D
C/E
10 S-Methyl-5′-thioadenosine
phosphorylase
Q13126 6.7/31.23 114 14/39 51 −2.7 4.6e–02
11 Phosphoglycerate mutase 1 P18669 6.7/28.80 284 17/17 75 −2.7 3.0e–03 A/D B/D
12 Triosephosphate Isomerase P60174 5.6/30.79 121 14/61 58 −3.2 3.5e–02
14 Myosin light polypeptide 6 P60660 4.6/16.93 105 11/41 68 −2.5 2.6e-02 C/E
15 Prefoldin subunit 2 Q9UHV9 6.2/16.65 101 11/32 54 −2.5 1.1e–02 C/E
16 Histidine triad nucleotide-
binding protein 1
P49773 6.4/13.80 105 8/14 77 −2.2 3.2e–02
L929
1 Vinculin Q64727 5.8/116.72 174 19/28 22 3.7 5.4e–03
2 Vimentin P20152 5.0/53.69 118 19/82 43 3.1 2.4e–03 A/E B/E C/E
3 Transitional endoplasmic
reticulum ATPase
Q01853 5.1/89.32 201 31/82 53 4.1 1.5e–03 A/E B/E C/E
5 Gelsolin P13020 5.1/85.94 188 23/51 36 4.8 1.5e–03 B/D C/D
6 Gelsolin P13020 5.1/85.94 83 14/48 20 7.6 4.2e–04 A/D B/D C/D
7 Gelsolin P13020 5.1/85.94 136 19/53 35 4.9 1.1e–02
8 NADH-ubiquinone
oxidoreductase 75 kDa
subunit, mitochondrial
Q91VD9 5.5/79.78 158 17/33 30 5.3 4.8e–06 A/D
A/E
B/D
B/E
C/D
C/E
9 Eukaryotic translation initiation
factor 4B
Q8BGD9 5.5/68.84 137 15/29 26 3.4 8.5e–04 B/D
B/E
C/D
C/E
10 Heat shock cognate 71 kDa
protein
P63017 5.4/70.87 267 34/70 56 4.2 8.8e–03
12 Stress-70 protein mitochondrial P38647 5.8/73.46 259 29/50 52 4.8 6.8e–03
13 Macrophage-capping protein P24452 6.7/39.24 95 11/32 38 4.2 2.5e–03 A/C
A/D
A/E
15 60S acidic ribosomal protein P0 P14869 5.9/34.22 160 14/29 56 5.5 1.1e–02
16 LIM and SH3 domain
protein 1
Q61792 6.6/29.99 172 16/29 44 3.1 1.5e–03 A/D
A/E
17 Heterogeneous nuclear
ribonucleoprotein D-like
Q3SWU3 9.1/35.29 104 11/34 34 3.7 3.2e–04 A/D
A/E
18 Aldose reductase P45376 6.7/35.73 195 18/51 61 3.4 4.4e–04 A/C
A/D
19 26S proteasome non-ATPase
regulatory subunit 9
Q9CR00 6.0/24.72 107 11/23 46 3.0 4.0e-02
22 Galectin-1 P16045 5.3/14.86 129 12/44 94 5.0 1.0e–03
23 Nucleoside diphosphate
kinase B
Q01768 7.0/17.36 158 15/46 73 7.3 7.6e–03 A/D
24 Nucleoside diphosphate
kinase A
P15532 6.8/17.21 177 15/36 80 5.7 2.8e–02 A/D
a) Spot numbers match those reported in the representative Coomassie Colloidal 2DE gels shown in Fig. 2.
b) Accession number in UniProtKB.
c) Predicted MW and pI in UniProtKB according to protein sequence.
d) Mascot score (matrix Science, London, UK; http://www.matrixscience.com).
e) Number of matched peptides correspond to peptide masses matching the top hit from Ms-Fit PMF.
f) Sequence coverage indicates (number of the identified residues/total number of amino acid residues in the protein sequence) × 100.
g) Fold change was calculated by SameSpot software. It is the ratio between the highest mean normalized volume and the lowest mean
normalized volume.
h) ANOVA p-value  0.05.
i) Tukey’s post ANOVA results. Different experimental conditions are indicated with letters: A) Untreated cells; B) incubated with empty 250
nm; C) incubated empty 500 nm; D) incubated with 205 Pd; incubated with 500 Pd.
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Figure 3. Functional classification and validation of
identified proteins. Proteins were classified by Panther
software (http://www.pantherdb.org) according to GO
classification. (A) HEK-293T and (B) L929 cells. (C)West-
ern blots with anti PGM-1 and anti Vimentin antibodies.
The intensity of immunostained bands was normalized
against the total protein intensities measured from the
same blot stained with Coomassie brilliant blue. (#) p-
value< 0.005 vs control (*) p-value< 0.0004 vs. 500/Pd.
are classified andgrouped infive categories.Most are involved
in “binding,” “structural molecule activity,” and “catalytic ac-
tivity.” To further validate the proteomic results we assayed
the protein expression levels of two selected proteins in to-
tal protein extracts from HEK-293T and L929 cells treated
with different types of nanospheres in comparison to un-
treated cells. We decided to validate the proteins involved in
themost affected functional categories, such as glycolisis and
cytoskeletal remodeling and we selected the proteins phos-
phoglycerate mutase for HEK-293T cells and vimentin for
L929 cells. Their amounts were measured by Western blot
analysis. Results, reported in Fig. 3, show that the expression
levels of phosphoglycerate mutase (C) and vimentin (D) are
significantly changed (less and more abundant, respectively),
in cells treated with Pd-conjugated nanospheres in compari-
son to controls and cells incubated with empty nanospheres.
3.5 Bioinformatics analysis of proteomic data
To establish whether the differentially expressed proteins
were associated with cellular pathways that were not directly
pointed out from the proteomic results, we performed a bioin-
formatics analysis byusing theweb-based tool BioProfiling.de
[26]. We separately uploaded two text files, with the 13 and
17 identified proteins, corresponding to the two different cel-
lular systems and we selected Homo sapiens for HEK293T
cells and Mus musculus for L929 cells as organisms. Fig-
ure 4 summarizes the results obtained for theHEK-293T cells
(A) and L929 cells (B) by using R-Spider. This tool analyzes
gene/protein list using as reference knowledge a global gene
network constructed by combining signaling and metabolic
pathways from reactome and KEGG databases [27]. In the
tables of Fig. 4 are shown the models’ definitions, which
specify the maximal allowed distance between two input pro-
teins connected, the number of input proteins covered by
the system, and the corresponding significance of the best
inferred model. As it is evident in panel A of Fig. 4, the in-
ferred network models D1 and D2 cover three proteins of the
13 used as input with a p-value estimated less than 0.005;
while the model D3 covers four proteins with a p-value less
than 0.03. We decided to analyze all these networks and we
reported the graphical illustrations of the protein–protein in-
teractions obtained by Cytoscape: http://www.cytoscape.org/
[28]. Since the network models D1 and D2 provided the same
results, we reported only the D1 and D3 illustrations. Three
proteins, belonging to metabolism of carbohydrates, are con-
nected in network model D1. The network D3 includes two
C© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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Figure 4. Bioinformatics analysis of dif-
ferently expressed proteins in response
to treatment with empty or Pd-conjugated
nanospheres obtained from HEK-293T (A)
and L929 cells (B). See manuscript for de-
tails.
intermediate proteins: glyceraldehydes-3-phosphate dehydro-
genase and phosphoglycerate kinase not detected in our pro-
teomic studies. Regarding the L929 cells results, only the
model D2 has a significant p-value less than 0.03. The cor-
responding graphical illustration of the network shows an
intermediate protein which is able to bind specifically to var-
ious cellular proteins containing SH2 domains.
4 Discussion
We demonstrated that the uptake ability using the 205Pd
is 20% higher for L929 cells in comparison to HEK-293T
cells, while the ability to internalize the 500Pd is compara-
ble between these two cell lines. The significant changes in
protein levels of cell incubated with the nanospheres are very
limited and these variations occur in both cell lines treated
with Pd-nanospheres in comparison to the empty one. No
key protein involved in cell cycle was found differentially ex-
pressed between treated and control cells. Only a negative
regulator of apoptosis (Anamorsin), results are more abun-
dant in HEK-293T cells following 48 h of incubation. In the
same cellular type we found as less abundant some proteins
implicated in transcription and protein folding control and
some enzymes involved in glycolysis. L929 cells aremore sus-
ceptible to nanosphere uptake than human cell line and all
identified proteins showed a more abundant expression level
after treatment. Among these, most are drawn in intracel-
lular transport: some are structural component of cytoskele-
ton, others are involved in actin filaments polymerization. All
these results corroborate the hypothesis previously proposed
according to which the uptake mechanism does not occur by
endocytosis, but through rapid cytoskeletal rearrangements
based on actin filaments polymerization [12]. Future studies
will be focused on the proteomic analysis of different cancer
cells treated with Pd-nanospheres together with antitumoral
prodrugs, to go one step closer to in vivo evaluation of this
promising therapeutic nanodevice.
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